A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
Launched by COOPERVISION INTERNATIONAL LIMITED (CVIL) · Mar 5, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two types of soft multifocal contact lenses: Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add. The main goal is to see which lens provides better overall satisfaction for people who need help with different types of vision problems, like seeing things up close and far away, often related to aging.
To participate, you need to be at least 18 years old and have been using soft contact lenses for the last three months. You should have specific vision needs, such as a certain level of reading correction and a certain range of eyesight measurements. However, some people may not qualify if they have certain eye or health conditions, like previous eye surgeries or specific eye disorders. If you decide to join, you will be asked to try both types of lenses and share your experiences with comfort and vision quality. This trial is currently recruiting participants, so it could be an excellent opportunity to contribute to research on better vision solutions for everyone!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. They are at least 18 years of age.
- • 2. They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent.
- • 3. They habitually use soft contact lenses (multifocal soft contact lenses, sphere lenses for monovision, sphere lenses for distance vision correction and spectacles for near vision correction,) and have done so for at least the past three months.
- • 4. They have a minimum reading add of +0.75DS (based on their spectacle refraction)
- • 5. They have spherical equivalent refractive error between +6.00 to -10.00DS at the corneal plane and refractive astigmatism of no greater than -0.75DC in each eye.
- • 6. They are able to achieve distance HCVA of +0.10 logMAR or better in each eye.
- Exclusion Criteria:
- • 1. They have an ocular disorder which would normally contra-indicate contact lens wear.
- • 2. They have a systemic disorder which would normally contra-indicate contact lens wear.
- • 3. They are aphakic.
- • 4. They have had corneal refractive surgery.
- • 5. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
About Coopervision International Limited (Cvil)
CooperVision International Limited (CVIL) is a leading global manufacturer of contact lenses and related products, dedicated to enhancing vision health and improving the quality of life for wearers worldwide. With a strong commitment to innovation and research, CVIL invests in clinical trials to develop advanced lens technologies and solutions tailored to diverse vision needs. The company operates with a focus on safety, efficacy, and customer satisfaction, ensuring that their products meet the highest standards of quality and performance. Through partnerships and collaborations, CVIL continues to drive advancements in the eye care industry while prioritizing patient outcomes and satisfaction.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berkeley, California, United States
Patients applied
Trial Officials
Meng C Lin, OD, Ph.D
Principal Investigator
UC Berkeley
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported